A new discovery by researchers at the University of Warwick could help stop bacteria being contaminated with viruses, reducing disruption and decreasing costs in industry and research. Bacteria are routinely used in biological and biomedical […]
Recipharm, a global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) as a manufacturing site of VOWST, a […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that the U.S. Food and […]
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it has closed a financing round of $20 million. The round was […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead […]
Royal DSM, a global science-based leader in health, nutrition and bioscience, announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication of Phase 2 study results from its lead program, VE303, in […]
Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, […]
Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has announced a JPY 1.1B investment in its Series A funding as of April, 2023. MGTx has been accelerating […]
In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified […]